跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,169 条关于
“Keynote-789”
全部
1,169
临床试验
486
药物
284
机构
5
资讯
394
2年前
KEYNOTE-789: Pembrolizumab Plus Chemotherapy Fails to Improve Survival in EGFR-Mutated NSCLC
去年
Merck Halts Final Phase 3 Keytruda Trial in Prostate Cancer After Failed Interim Analysis
去年
Benmelstobart Plus Anlotinib Shows Promise in EGFR-Mutated NSCLC After TKI Failure
2年前
Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC
去年
Lantheus Completes $789 Million Acquisition of Life Molecular Imaging, Gains FDA-Approved Alzheimer's Diagnostic Agent
去年
Pembrolizumab Plus Chemotherapy Improves Overall Survival in HER2-Positive Gastric Cancer
2年前
Pembrolizumab Demonstrates Sustained Survival Benefits in Advanced Melanoma After 10-Year Follow-Up
2年前
Pembrolizumab Improves Overall Survival in Clear Cell Renal Cell Carcinoma
3个月前
The Evolving Role of Biotechnology Keynote Speakers in Shaping Pharmaceutical R&D Strategy
2年前
Pembrolizumab Shows Sustained Survival Benefit in Advanced Melanoma After 10-Year Follow-up
第 1 页,共 40 页
上一页
下一页